View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Cl...

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology ― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial― ― Topline data for the Phase 3 REACH clinical trial of losmapimod in FSHD expected during 4Q’24― CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-sta...

Jonathan Chaplin
  • Jonathan Chaplin

What happened to the US broadband market?

We have covered a lot of ground on the broadband sector over the last two weeks. I thought it might help to pull together some of the more important threads, in case you missed them during the busy reporting seasons.

 PRESS RELEASE

Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conf...

Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2024 financial results will be released on Monday, May 13, 2024 before the U.S. financial markets open. Management will host a conference call and webcast a...

Jonathan Chaplin
  • Jonathan Chaplin

Autumn for Broadband 1Q24

In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Industry net adds were substantially weaker in 1Q24 with all technologies seeing slower growth (except DSL which was flat). Cable was impacted the most.

 PRESS RELEASE

The Tile Shop to Host First Quarter 2024 Earnings Conference Call

The Tile Shop to Host First Quarter 2024 Earnings Conference Call MINNEAPOLIS, May 02, 2024 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, setting and maintenance materials and related accessories, today announced that the Company will release financial results for the first quarter ended March 31, 2024 at 7:00 a.m. Eastern Time on Thursday, May 9, 2024.   The Company will host a conference call via webcast for investors and other interested parties beginning at 9:00 a.m. Eastern Time on...

FMC Corporation: Key facts and statistics - 2023

A summary company profile, detailing FMC Corporation’s business operations and financial highlights.

 PRESS RELEASE

AtriCure Reports First Quarter 2024 Financial Results

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results. “We are proud to announce a strong start to 2024, marked by growth across each of our franchises worldwide,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “We remain diligently focused on expanding the reach of our solutions for patients with advanced forms of Afib, managing the LAA in patients undergoing cardiac sur...

Jonathan Chaplin
  • Jonathan Chaplin

LUMN quick hit: big improvement in fiber adds

We touch on Lumen’s fiber trends in this note and the implications for our broader broadband thesis in this brief note.

 PRESS RELEASE

AtriCure to Participate in the 2024 Bank of America Securities Healthc...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Bank of America Securities Healthcare Conference. AtriCure’s management is scheduled to present on Tuesday, May 14, 2024, at 10:15 a.m. Pacific Daylight Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at . About AtriCure AtriCure, Inc. provides innovat...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Antoine Legault ... (+2)
  • Antoine Legault
  • Gerald Pascarelli
Antoine Legault ... (+2)
  • Antoine Legault
  • Gerald Pascarelli
 PRESS RELEASE

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with full launch expected by the end of the second quarter. “cryoSPHERE+ is a meaningful innovation that I believe will improve...

 PRESS RELEASE

Absci to Report Business Updates and First Quarter 2024 Financial and ...

Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024 VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, May 14, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial a...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: April 12, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Lumen Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its geographic, revenue and client diversification, constrained by its elevated debt levels and its negative revenue and EBITDA trends.

 PRESS RELEASE

AtriCure to Announce First Quarter 2024 Financial Results

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, May 1, 2024, to discuss its first quarter 2024 financial results. Those interested in listening to the conference call should . Participants are encouraged to register more than 15 minutes before the start of the cal...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch